Primary source: Inspections and Compliance
FDA granted accelerated approval for Etcamah (camizestrant), necessitating updates to labeling, compliance documentation, and monitoring processes.
This approval signifies a new targeted therapy for patients with advanced breast cancer, addressing an unmet medical need and enabling earlier intervention based on personalized medicine.
Update product labeling to include new efficacy data and boxed warnings, incorporate the new treatment into compliance protocols, and increase monitoring for adverse events associated with Etcamah.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Update product labeling to include new efficacy data and boxed warnings, incorporate the new treatment into compliance protocols, and increase monitoring for adverse events associated with Etcamah.
The U.S. FDA has expanded treatment options for adult patients with hormone receptor-positive, HER2-negative, advanced breast cancer by granting accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor. This treatment is specifically for patients with detected ESR1 mutations during previous therapies. Confirmatory studies are required to evaluate clinical benefits, and a companion diagnostic, the Guardant360 CDx assay, has been authorized to identify eligible patients.
What changed: FDA granted accelerated approval for Etcamah (camizestrant), necessitating updates to labeling, compliance documentation, and monitoring processes.
Why it matters: This approval signifies a new targeted therapy for patients with advanced breast cancer, addressing an unmet medical need and enabling earlier intervention based on personalized medicine.
Practical implication: Update product labeling to include new efficacy data and boxed warnings, incorporate the new treatment into compliance protocols, and increase monitoring for adverse events associated with Etcamah.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.
Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.
Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.
